Hosten, Benoît <br/><br/>
Recombinant interleukin-2 pre-treatment increases anti-tumor response to paclitaxel by affecting lung P-glycoprotein expression on the Lewis lung carcinoma.  [electronic resource] 

 -  Anti-cancer drugs  Feb 2006 
 - 195-9 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0959-4973 
<br/><br/><label>Standard No.: </label>10.1097/00001813-200602000-00011  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>ATP Binding Cassette Transporter, Subfamily B, Member 1--metabolism<br/>Administration, Oral<br/>Animals<br/>Antineoplastic Agents, Phytogenic--administration & dosage<br/>Blotting, Western<br/>Carcinoma, Lewis Lung--drug therapy<br/>Combined Modality Therapy<br/>Female<br/>Injections, Subcutaneous<br/>Interleukin-2--therapeutic use<br/>Lung--drug effects<br/>Mice<br/>Mice, Inbred C57BL<br/>Paclitaxel--administration & dosage<br/>Recombinant Proteins--therapeutic use